Shanghai United Imaging Healthcare

Shanghai United Imaging Healthcare, commonly known as United Imaging, is a Chinese medical-technology company headquartered in Shanghai. Its business centers on the design, development, manufacture, sale, and service of advanced healthcare equipment and digital clinical solutions. The company is best known for medical-imaging systems, including computed tomography, magnetic resonance imaging, molecular-imaging equipment, digital radiography, and related information and workflow technologies. It also develops radiotherapy systems, ultrasound products, and equipment intended for research and life-science applications. The company was established in 2011 during a period in which China was seeking to strengthen domestic capabilities in high-end medical equipment. United Imaging positioned itself as an integrated technology developer rather than a narrowly focused equipment supplier. Its product portfolio spans hardware, software, clinical applications, service, and system integration, allowing it to address hospitals, imaging centers, research institutions, and other healthcare organizations. This broad approach has enabled the company to compete in equipment categories historically dominated in China by large multinational manufacturers. United Imaging's technology strategy emphasizes high-end systems, digital connectivity, automation, and the use of artificial intelligence and data analysis in clinical workflows. Its offerings are used in areas such as oncology, cardiology, neurology, emergency medicine, general diagnosis, radiotherapy planning, and scientific research. The company has promoted locally developed platforms with the aim of improving access to advanced equipment, supporting domestic supply chains, and adapting systems to the needs of Chinese hospitals while also pursuing international sales. The company expanded from a China-focused medical-equipment developer into an international supplier through overseas subsidiaries, service infrastructure, regulatory approvals, and placements of equipment in markets outside China. Its international activities include sales and support in North America, Europe, and other regions, although its largest commercial base remains China. In addition to selling individual systems, the company has participated in hospital and imaging-center projects that involve multiple modalities, installation, maintenance, and digital integration. United Imaging became a publicly traded company when Shanghai United Imaging Healthcare Co., Ltd. completed its listing on the Shanghai Stock Exchange STAR Market in 2022 under ticker 688271. The public offering increased its visibility as one of China's prominent medical-device technology companies and provided capital for research and development, manufacturing capacity, commercialization, and international expansion. The listed entity continues to operate as an active healthcare-equipment company. Specific current executive assignments, ownership details beyond public-company disclosures, and product-by-product commercial availability should be verified against the latest company filings and official product pages.

United Imaging Healthcare was established in Shanghai in 2011 with the objective of developing high-end medical equipment in China. Its formation reflected a broader effort to build domestic capabilities in sophisticated healthcare technologies, including imaging and radiotherapy, where hospitals had historically relied heavily on multinational suppliers. The company was founded around a research-and-development-led model and sought to combine engineering, clinical application development, manufacturing, and service within one organization. During its early development, United Imaging concentrated on medical imaging and related clinical technologies. It developed product families covering computed tomography, magnetic resonance imaging, molecular imaging, and digital radiography. Rather than limiting its role to individual instruments, the company also invested in software, workflow, system integration, and clinical applications. This allowed it to present hospitals with broader technology platforms and to compete for projects involving multiple departments or modalities. A notable part of the company's development was its pursuit of high-performance systems intended for demanding clinical and research uses. The portfolio expanded into total-body imaging, advanced magnetic resonance, positron-emission tomography, radiotherapy, ultrasound, and life-science applications. United Imaging also emphasized the use of artificial intelligence, automation, image reconstruction, and digital connectivity to improve examination efficiency and clinical interpretation. These efforts helped distinguish the company from lower-cost suppliers focused mainly on basic equipment. The company grew its manufacturing, sales, installation, and service capabilities in China while developing an international presence. It established overseas commercial and support activities and sought regulatory clearances and customer placements outside its home market. International expansion broadened the company's customer base and provided an opportunity to test its products in healthcare systems with different procurement, regulatory, and clinical requirements. China nevertheless remained the central market for its business and product deployment. United Imaging's public-market transition occurred in 2022, when Shanghai United Imaging Healthcare Co., Ltd. listed on the Shanghai Stock Exchange STAR Market under ticker 688271. The listing increased the company's access to capital and public visibility. Its stated areas of development continued to include medical imaging, radiotherapy, digital healthcare, life-science products, research and development, manufacturing, and global commercialization. Today, United Imaging is an active Chinese medical-technology brand with a portfolio spanning imaging, therapy, healthcare IT, and research equipment. It is one of the better-known domestic challengers to established international imaging manufacturers in China. Its long-term development depends on continued innovation, regulatory approvals, hospital adoption, service quality, reimbursement and procurement conditions, and the ability to translate high-end product development into reliable commercial deployments across China and international markets.

1. 2022STAR Market listing

   Shanghai United Imaging Healthcare Co., Ltd. became publicly traded on the Shanghai Stock Exchange STAR Market under ticker 688271.

   Source
2. 2011Company established

   Shanghai United Imaging Healthcare was established in Shanghai to develop and commercialize high-end medical equipment and related healthcare technologies.

   Source

A Chinese high-end medical-technology manufacturer positioned around vertically integrated innovation in diagnostic imaging, radiotherapy, digital healthcare, and life-science equipment, with ambitions to serve both domestic and international markets.

• uCT seriesComputed tomography

  The uCT portfolio covers computed tomography systems for general diagnostic imaging and more specialized clinical applications. Depending on the model, systems are designed around high-speed acquisition, image reconstruction, dose management, automation, and workflow integration. CT products can support routine examinations as well as emergency, cardiovascular, oncology, and other demanding imaging settings.

• uMR seriesMagnetic resonance imaging

  The uMR family consists of magnetic resonance systems serving clinical imaging departments and advanced research environments. The range includes systems intended for different field strengths and clinical workloads, with emphasis on image quality, examination efficiency, patient positioning, motion management, and software-assisted workflow. Applications include neurology, musculoskeletal imaging, abdominal imaging, oncology, and cardiovascular work.

• uEXPLORERTotal-body PET/CT

  uEXPLORER is a total-body PET/CT platform designed to image a much larger portion of the body than conventional PET systems in a single acquisition. Its design supports research into whole-body tracer distribution and may enable high-sensitivity imaging, shorter scans, or reduced tracer use in appropriate clinical and research protocols. It is associated particularly with molecular imaging and translational research.

• uMI seriesMolecular imaging

  The uMI portfolio includes PET/CT and related molecular-imaging systems used to visualize physiological processes and disease activity. These systems are relevant to oncology, neurology, cardiology, and research applications. Product configurations are designed to balance sensitivity, spatial resolution, acquisition speed, patient throughput, and integration with CT-based anatomical information.

• uRT seriesRadiotherapy

  The uRT range covers radiotherapy equipment and associated treatment-planning or workflow technologies. These products are intended to support the delivery of radiation treatment for cancer while integrating imaging, positioning, planning, and treatment management. The portfolio reflects United Imaging's expansion beyond diagnosis into oncology therapy and the broader cancer-care pathway.

• uDR seriesDigital radiography

  The uDR family comprises digital X-ray and radiography systems for routine hospital and outpatient imaging. Products in this category are designed for general radiography workflows, including chest, skeletal, emergency, and other common examinations. Depending on the configuration, the systems can include automated positioning, digital detectors, image-processing software, and department-level workflow tools.

• uMR OMEGATotal-body magnetic resonance imaging

  uMR OMEGA is a total-body magnetic resonance platform associated with high-coverage imaging and advanced clinical or research applications. Its development reflects United Imaging's effort to extend MRI beyond conventional anatomical examinations toward broader whole-body and quantitative imaging workflows. Availability and precise configuration may vary by jurisdiction and regulatory status.

• 2022Public-market financing and expansionStrategy

  The company pursued a STAR Market listing while continuing to invest in high-end medical-equipment research, manufacturing, clinical commercialization, and international expansion.

  What changed. Shanghai United Imaging Healthcare Co., Ltd. completed its listing on the Shanghai Stock Exchange STAR Market under ticker 688271.

  Aftermath. The listing made the company a publicly traded medical-technology group and provided a new source of capital and public-market visibility.

  Source

• 2022United Imaging Healthcare listed on the Shanghai Stock Exchange STAR Market

  Shanghai United Imaging Healthcare Co., Ltd. completed its public listing on the STAR Market under ticker 688271, marking a major corporate-finance milestone and supporting continued investment in research, manufacturing, and market expansion.

  M&A
  Source

1. United Imaging Healthcare official website
2. Shanghai Stock Exchange